Massive Bio partners with Sequence Me Now to connect cancer patients to trials

Massive Bio and Sequence Me Now announced a partnership July 13 to steer cancer patients from genomic testing to AI-powered clinical trial matching. The move links self-advocacy tools with trial access as both groups push personalized medicine for more patients.

Why it matters: - The partnership gives cancer patients a clearer path from biomarker testing to trial options. - Sequence Me Now patients can now move from self-advocacy resources to a clinical-trial matching tool without starting their search from scratch. - The setup could help patients who have genomic results but are unsure what they mean for treatment.

What happened: - Massive Bio announced a new partnership with Sequence Me Now on July 13, 2026. - Sequence Me Now is a nonprofit patient advocacy organization focused on genomic sequencing and personalized medicine. - Massive Bio is featured on the “Find a Trial” page of Sequence Me Now’s website. - Massive Bio also created a dedicated landing page for Sequence Me Now patients to submit intake information and explore possible trial matches.

The details: - Sequence Me Now’s Sequence Code is a five-step patient playbook founded by Bryce Olson, who used genomic sequencing results to outlast an initial 21-month prognosis by nine years. - The nonprofit’s mission, “Power to the Patient,” is to give patients tools and vocabulary to demand biomarker testing, understand results and pursue matching treatments and trials. - Massive Bio uses artificial intelligence to help cancer patients identify clinical trials they may be eligible for. - The company’s platform matches patients based on diagnosis and biomarker profile. - Arturo Loaiza-Bonilla, Massive Bio’s co-founder and chief medical AI officer, said many patients get sequencing results and do not know what to do next. - Toygun Rauf Onaran, Massive Bio’s SVP of U.S. provider engagement and partnerships, said the partnership gives Sequence Me Now patients a clear next step toward a trial that may fit them. - Hans George, chair of Sequence Me Now’s board, said the Sequence Code is a curated roadmap for patients who refuse to accept they have run out of options.

Between the lines: - The partnership pairs patient education with a practical access point, which can matter because genomic testing only helps if patients can act on the results. - The collaboration also extends both organizations’ messages about personalized medicine, trial access and patient self-advocacy. - Massive Bio is positioning its AI matching as a downstream step after patients complete the Sequence Code and have biomarker data in hand.

What's next: - Sequence Me Now patients who use the “Find a Trial” page can move into Massive Bio’s intake flow to look for available studies. - Both groups are likely to use the partnership to funnel more patients from testing into trial consideration. - Massive Bio directs readers to more information. - Sequence Me Now directs readers to learn more.